<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="221306">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00202540</url>
  </required_header>
  <id_info>
    <org_study_id>CL2-18986-009</org_study_id>
    <nct_id>NCT00202540</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients</brief_title>
  <official_title>Efficacy of 15 mg and 50 mg of S18986 on Cognitive Symptoms in Mild Cognitive Impairment Patients Treated Over a 12-month Oral Administration Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Servier</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate a long term efficacy of S18986 versus placebo on
      episodic memory performance in patients with MCI
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">March 29, 2006</completion_date>
  <primary_completion_date type="Actual">March 29, 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double Blind (masked roles unspecified)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Episodic memory</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other cognitive domains, activities of daily living, global impression of change, MRI, safety.</measure>
  </secondary_outcome>
  <enrollment type="Actual">38</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S18986</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Memory complaint

          -  Acetylcholinesterase inhibitors stopped at least 3 months before selection

        Exclusion Criteria:

          -  Dementia

          -  Parkinson's disease

          -  Vascular disorder

          -  Depression

          -  Epilepsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Vellas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital la Grave-Casselardit, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital la Grave-Casselardit</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 5, 2017</lastchanged_date>
  <firstreceived_date>September 12, 2005</firstreceived_date>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cognition Disorders</mesh_term>
    <mesh_term>Mild Cognitive Impairment</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
